Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
ConditionChronic Pulmonary Aspergillosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorImperial College London
About this trial
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients >/= 18 years old and able to provide informed consent
Patients with a diagnosis of chronic pulmonary aspergillosis
To speak and understand English
Able to provide informed consent
Disqualifiers
None
Trial population
Individuals with confirmed Chronic Pulmonary Aspergillosis
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.
To develop and validate a novel disease-specific health-related quality of life (HRQoL) measure in chronic pulmonary aspergillosis (CPA): The Chronic Pulmonary Aspergillosis Health Assessment Questionnaire (CPA-HAQ)
Time frame
30 monthsSecondary outcomes
1
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.
Testing the usability of a newly developed CPA-HAQ measure.
Time frame
30 months2
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.
Correlating how HRQoL outcomes relate to existing disease prognostic markers.
Time frame
30 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Imperial College London
Lead sponsor
Manchester University NHS Foundation Trust
Collaborator
Tayside Medical Science Centre
Collaborator
Source ClinicalTrials.gov